{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T16:58:22Z","timestamp":1744736302493},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1016\/j.beha.2006.05.004","type":"journal-article","created":{"date-parts":[[2006,9,23]],"date-time":"2006-09-23T11:29:43Z","timestamp":1159010983000},"page":"669-684","source":"Crossref","is-referenced-by-count":9,"title":["Radioimmunotherapeutic strategies in autologous hematopoietic stem-cell transplantation for malignant lymphoma"],"prefix":"10.1016","volume":"19","author":[{"given":"David J.","family":"Inwards","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey C.","family":"Cilley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane N.","family":"Winter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.beha.2006.05.004_bib1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"The New England Journal of Medicine"},{"issue":"11","key":"10.1016\/j.beha.2006.05.004_bib2","first-page":"6a","article-title":"Phase III trial of rituximab-CHOP (R-CHOP) vs. CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLDCL)","volume":"102","author":"Habermann","year":"2003","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2006.05.004_bib3","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1080\/10428190500217312","article-title":"Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma","volume":"46","author":"Vose","year":"2005","journal-title":"Leukemia & Lymphoma"},{"issue":"23","key":"10.1016\/j.beha.2006.05.004_bib4","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"The New England Journal of Medicine"},{"issue":"6","key":"10.1016\/j.beha.2006.05.004_bib5","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1083-8791(01)80003-3","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidence-based review","volume":"7","author":"Hahn","year":"2001","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"4","key":"10.1016\/j.beha.2006.05.004_bib6","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","article-title":"Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University","volume":"14","author":"Mac Manus","year":"1996","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"11","key":"10.1016\/j.beha.2006.05.004_bib7","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1200\/JCO.2003.07.111","article-title":"Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma","volume":"21","author":"Seymour","year":"2003","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"12","key":"10.1016\/j.beha.2006.05.004_bib8","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2006.05.004_bib9","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1200\/JCO.2005.06.146","article-title":"Meta-analysis to evaluate the role of interferon in follicular lymphoma","volume":"23","author":"Rohatiner","year":"2005","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"14_supplement","key":"10.1016\/j.beha.2006.05.004_bib10","doi-asserted-by":"crossref","first-page":"6502","DOI":"10.1200\/jco.2004.22.14_suppl.6502","article-title":"Results of E1496: a phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL)","volume":"22","author":"Hochster","year":"2004","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"21","key":"10.1016\/j.beha.2006.05.004_bib11","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"10","key":"10.1016\/j.beha.2006.05.004_bib12","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"van Besien","year":"2003","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.beha.2006.05.004_bib13","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.beha.2006.05.004_bib14","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1083-8791(00)70030-9","article-title":"Autologous hematopoietic stem cell transplantation for mantle cell lymphoma","volume":"6","author":"Vose","year":"2000","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"7","key":"10.1016\/j.beha.2006.05.004_bib15","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2006.05.004_bib16","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/annonc\/mdi107","article-title":"Hematopoietic stem cell transplantation in mantle cell lymphoma","volume":"16","author":"Ganti","year":"2005","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology\/ESMO"},{"issue":"2 supplement 4","key":"10.1016\/j.beha.2006.05.004_bib17","first-page":"10","article-title":"Radioimmunotherapy for non-Hodgkin's lymphomas: a historical perspective","volume":"30","author":"Press","year":"2003","journal-title":"Seminars in Oncology"},{"issue":"11","key":"10.1016\/j.beha.2006.05.004_bib18","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1200\/JCO.1992.10.11.1696","article-title":"Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma","volume":"10","author":"Kaminski","year":"1992","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"23 supplement","key":"10.1016\/j.beha.2006.05.004_bib19","first-page":"5899s","article-title":"Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody","volume":"55","author":"Juweid","year":"1995","journal-title":"Cancer Research"},{"issue":"12","key":"10.1016\/j.beha.2006.05.004_bib20","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","article-title":"Phase I\/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma","volume":"17","author":"Witzig","year":"1999","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"15","key":"10.1016\/j.beha.2006.05.004_bib21","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"7","key":"10.1016\/j.beha.2006.05.004_bib22","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJM199308123290703","article-title":"Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody","volume":"329","author":"Kaminski","year":"1993","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.beha.2006.05.004_bib23","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.V96.4.1259","article-title":"Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience","volume":"96","author":"Kaminski","year":"2000","journal-title":"Blood"},{"issue":"supplement 1","key":"10.1016\/j.beha.2006.05.004_bib24","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.3816\/CLM.2004.s.003","article-title":"Radioimmunotherapy in non-Hodgkin's lymphoma: trials of yttrium 90-labeled ibritumomab tiuxetan and beyond","volume":"5","author":"Evens","year":"2004","journal-title":"Clinical Lymphoma"},{"issue":"2","key":"10.1016\/j.beha.2006.05.004_bib25","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1634\/theoncologist.9-2-160","article-title":"Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma","volume":"9","author":"Vose","year":"2004","journal-title":"Oncologist"},{"issue":"16","key":"10.1016\/j.beha.2006.05.004_bib26","first-page":"4935","article-title":"Determinants of the antitumor effect of radiolabeled monoclonal antibodies","volume":"50","author":"Knox","year":"1990","journal-title":"Cancer Research"},{"issue":"7","key":"10.1016\/j.beha.2006.05.004_bib27","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.1996.14.7.1974","article-title":"Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma","volume":"14","author":"Kaminski","year":"1996","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.beha.2006.05.004_bib28","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2000.18.6.1316","article-title":"Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed\/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas","volume":"18","author":"Vose","year":"2000","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"19","key":"10.1016\/j.beha.2006.05.004_bib29","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"5","key":"10.1016\/j.beha.2006.05.004_bib30","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"The New England Journal of Medicine"},{"issue":"31","key":"10.1016\/j.beha.2006.05.004_bib31","doi-asserted-by":"crossref","first-page":"7985","DOI":"10.1200\/JCO.2005.01.0892","article-title":"Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab","volume":"23","author":"Kaminski","year":"2005","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.beha.2006.05.004_bib32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1358\/dot.2004.40.2.799423","article-title":"Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma","volume":"40","author":"Witzig","year":"2004","journal-title":"Drugs of Today (Barcelona, Spain: 1998)"},{"issue":"3","key":"10.1016\/j.beha.2006.05.004_bib33","first-page":"457","article-title":"Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma","volume":"2","author":"Knox","year":"1996","journal-title":"Clinical Cancer Research: an Official Journal of the American Association for Cancer Research"},{"issue":"10","key":"10.1016\/j.beha.2006.05.004_bib34","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"11","key":"10.1016\/j.beha.2006.05.004_bib35","first-page":"406a","article-title":"A phase I trial of two-sequential doses of ZevalinTM radioimmunotherapy for relapsed low-grade B-cell non-Hodgkin's lymphoma","volume":"102","author":"Witzig","year":"2003","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.beha.2006.05.004_bib36","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJM199310213291702","article-title":"Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support","volume":"329","author":"Press","year":"1993","journal-title":"The New England Journal of Medicine"},{"issue":"8971","key":"10.1016\/j.beha.2006.05.004_bib37","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0140-6736(95)92225-3","article-title":"Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas","volume":"346","author":"Press","year":"1995","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.beha.2006.05.004_bib38","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.1998.16.10.3270","article-title":"Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue","volume":"16","author":"Liu","year":"1998","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"11","key":"10.1016\/j.beha.2006.05.004_bib39","first-page":"487","article-title":"A Phase II Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults \u226560 Years of Age with High-Risk Relapsed or Refractory B-Cell Lymphoma","volume":"106","author":"Gopal","year":"2005","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"11","key":"10.1016\/j.beha.2006.05.004_bib40","first-page":"897","article-title":"Dose Finding Trial of Yttrium 90 (90Y) Ibritumomab Tiuxetan with Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)","volume":"104","author":"Flinn","year":"2004","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"11","key":"10.1016\/j.beha.2006.05.004_bib41","first-page":"488","article-title":"High Dose Zevalin (90Yttrium Ibritumomab Tiuxetan) Treatment with PBSC Support in Refractory-Resistant NHL Patients: Preliminary Results of a Phase I\/II Study","volume":"106","author":"Vanazzi","year":"2005","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"11","key":"10.1016\/j.beha.2006.05.004_bib42","first-page":"2737","article-title":"High-Dose Myeloablative Zevalin Radioimmunotherapy with Tandem Stem-Cell Autografting Has Minimal Toxicity and Full Feasibility in an Outpatient Setting","volume":"106","author":"Devizzi","year":"2005","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"9","key":"10.1016\/j.beha.2006.05.004_bib43","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood.V96.9.2934","article-title":"A phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas","volume":"96","author":"Press","year":"2000","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2006.05.004_bib44","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1200\/JCO.2005.05.117","article-title":"Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma","volume":"23","author":"Vose","year":"2005","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"supplement 5","key":"10.1016\/j.beha.2006.05.004_bib45","first-page":"100","article-title":"Yttrium 90 (90Y) ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma (NHL): incorporation into autologous stem cell transplantation (ASCT) regimens","volume":"16","author":"Nademanee","year":"2005","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology\/ESMO"},{"issue":"supplement 5","key":"10.1016\/j.beha.2006.05.004_bib46","first-page":"100","article-title":"Zevalin (90YZ) doses >.5 mci\/kg may be combined with high-dose BEAM and autotransplant (ASCT)","volume":"16","author":"Winter","year":"2005","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology\/ESMO"},{"issue":"8","key":"10.1016\/j.beha.2006.05.004_bib47","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood-2005-03-1310","article-title":"A phase 1\/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma","volume":"106","author":"Nademanee","year":"2005","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2006.05.004_bib48","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2003-02-0622","article-title":"High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis","volume":"102","author":"Gopal","year":"2003","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2006.05.004_bib49","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood.V99.9.3158","article-title":"High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma","volume":"99","author":"Gopal","year":"2002","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2006.05.004_bib50","first-page":"681","article-title":"New Transplant Strategies Utilizing Radioimmunotherapy (RIT) Based Regimens To Reduce Relapse in High Risk Mantle Cell Lymphoma (MCL)","volume":"106","author":"Krishnan","year":"2005","journal-title":"ASH Annual Meeting Abstracts"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692606000363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692606000363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T09:24:29Z","timestamp":1587201869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692606000363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["S1521692606000363"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2006.05.004","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}